Generic-drug maker Sandoz will start selling an alternative to the EpiPen in the U.S. early next year. Brand-name EpiPen, which dominates the market, has been in short supply since spring because of production problems.
Drugmaker to sell cheaper generic rival to EpiPen injectors
